Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 13, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 675,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,485 pence per share; lowest price paid was 1,470.5 pence per share.
- Treasury Holdings (Settled): 487,357,927 shares, representing 8.91% of total issued share capital.
- Treasury Holdings (Including Unsettled): 489,232,927 shares, representing 9.82% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,984,418,259 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 675,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.82% when including unsettled purchases. The filing does not provide comparative financial data to assess changes in operational performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (487,357,927 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 8.91% Treasury ownership calculation.
- Check the status of the 1,875,000 shares (difference between settled and total Treasury holdings) to determine if they have since settled.
- Review the remaining authorization for share buybacks under the May 3, 2012 shareholder mandate.